Table of Contents
ISRN Endocrinology
Volume 2013, Article ID 636927, 9 pages
http://dx.doi.org/10.1155/2013/636927
Review Article

Risk of Cancer in Diabetes: The Effect of Metformin

Endocrine Research Center (Firouzgar), Institute of Endocrinology and Metabolism, Tehran University of Medical Sciences, Tehran 15937-48711, Iran

Received 20 July 2013; Accepted 16 August 2013

Academic Editors: A. Kautzky-Willer and N. Tentolouris

Copyright © 2013 Mojtaba Malek et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Ko and S. Chaudhry, “The need for a multidisciplinary approach to cancer care,” Journal of Surgical Research, vol. 105, no. 1, pp. 53–57, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Noto, T. Tsujimoto, T. Sasazuki, and M. Noda, “Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis,” Endocrine Practice, vol. 17, no. 4, pp. 616–628, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Deng, Z. Gui, L. Zhao, J. Wang, and L. Shen, “Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis,” Digestive Diseases and Sciences, vol. 57, no. 6, pp. 1576–1585, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Jiang, Q. Ben, H. Shen, W. Lu, Y. Zhang, and J. Zhu, “Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies,” European Journal of Epidemiology, vol. 26, no. 11, pp. 863–876, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. H. U. Krämer, B. Schöttker, E. Raum, and H. Brenner, “Type 2 diabetes mellitus and colorectal cancer: meta-analysis on sex-specific differences,” European Journal of Cancer, vol. 48, pp. 1269–1282, 2012. View at Google Scholar
  6. P. Boyle, M. Boniol, A. Koechlin et al., “Diabetes and breast cancer risk: a meta-analysis,” British Journal of Cancer, vol. 107, pp. 1608–1617, 2012. View at Google Scholar
  7. P. J. Hardefeldt, G. D. Eslick, and S. Edirimanne, “Benign thyroid disease is associated with breast cancer: a meta-analysis,” Breast Cancer Research and Treatment, vol. 133, no. 3, pp. 1169–1177, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Tian, L. Q. Zhang, X. H. Ma, J. N. Zhou, and J. Shen, “Diabetes mellitus and incidence and mortality of gastric cancer: a meta-analysis,” Experimental and Clinical Endocrinology and Diabetes, vol. 120, no. 4, pp. 217–223, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. Z. Ge, Q. Ben, J. Qian, Y. Wang, and Y. Li, “Diabetes mellitus and risk of gastric cancer: a systematic review and meta-analysis of observational studies,” European Journal of Gastroenterology and Hepatology, vol. 23, no. 12, pp. 1127–1135, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. R. J. Stevens, A. W. Roddam, and V. Beral, “Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis,” British Journal of Cancer, vol. 96, no. 3, pp. 507–509, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. Q. Ben, M. Xu, X. Ning et al., “Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies,” European Journal of Cancer, vol. 47, no. 13, pp. 1928–1937, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. S. C. Larsson and A. Wolk, “Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies,” Diabetologia, vol. 54, no. 5, pp. 1013–1018, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Bansal, A. Bhansali, G. Kapil et al., “Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies,” Prostate Cancer and Prostatic Diseases, vol. 16, no. 2, pp. 151–158, 2013. View at Publisher · View at Google Scholar
  14. K. S. Peairs, B. B. Barone, C. F. Snyder et al., “Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis,” Journal of Clinical Oncology, vol. 29, no. 1, pp. 40–46, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Noto, K. Osame, T. Sasazuki, and M. Noda, “Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan,” Journal of Diabetes and its Complications, vol. 24, no. 5, pp. 345–353, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Lann and D. LeRoith, “The role of endocrine insulin-like growth factor-I and insulin in breast cancer,” Journal of Mammary Gland Biology and Neoplasia, vol. 13, no. 4, pp. 371–379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. I. R. Hsu, S. P. Kim, M. Kabir, and R. N. Bergman, “Metabolic syndrome, hyperinsulinemia, and cancer,” The American Journal of Clinical Nutrition, vol. 86, no. 3, pp. S867–S871, 2007. View at Google Scholar · View at Scopus
  18. R. Novosyadlyy and D. LeRoith, “Hyperinsulinemia and type 2 diabetes: impact on cancer,” Cell Cycle, vol. 9, no. 8, pp. 1449–1450, 2010. View at Google Scholar · View at Scopus
  19. A. G. Renehan, M. Zwahlen, C. Minder, S. T. O'Dwyer, S. M. Shalet, and M. Egger, “Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis,” The Lancet, vol. 363, no. 9418, pp. 1346–1353, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Giovannucci, “Insulin, insulin-like growth factors and colon cancer: a review of the evidence,” Journal of Nutrition, vol. 131, no. 11, pp. 3109S–3120S, 2001. View at Google Scholar · View at Scopus
  21. I. Tripkovic, A. Tripkovic, M. Strnad, V. Capkun, and L. Zekan, “Role of insulin-like growth factor-1 in colon cancerogenesis: a Case-Control Study,” Archives of Medical Research, vol. 38, no. 5, pp. 519–525, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. R. E. Schoen, C. M. Tangen, L. H. Kuller et al., “Increased blood glucose and insulin, body size, and incident colorectal cancer,” Journal of the National Cancer Institute, vol. 91, no. 13, pp. 1147–1154, 1999. View at Google Scholar · View at Scopus
  23. R. Kaaks, P. Toniolo, A. Akhmedkhanov et al., “Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women,” Journal of the National Cancer Institute, vol. 92, no. 19, pp. 1592–1600, 2000. View at Google Scholar · View at Scopus
  24. S. H. Saydah, E. A. Platz, N. Rifai, M. N. Pollak, F. L. Brancati, and K. J. Helzlsouer, “Association of markers of insulin and glucose control with subsequent colorectal cancer risk,” Cancer Epidemiology Biomarkers and Prevention, vol. 12, no. 5, pp. 412–418, 2003. View at Google Scholar · View at Scopus
  25. P. Stattin, A. Lukanova, C. Biessy et al., “Obesity and colon cancer: does leptin provide a link?” International Journal of Cancer, vol. 109, no. 1, pp. 149–152, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. E. K. Wei, J. Ma, M. N. Pollak et al., “A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 4, pp. 850–855, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Toniolo, P. F. Bruning, A. Akhmedkhanov et al., “Serum insulin-like growth factor-I and breast cancer,” International Journal of Cancer, vol. 88, pp. 828–832, 2000. View at Google Scholar
  28. P. Muti, T. Quattrin, B. J. B. Grant et al., “Fasting glucose is a risk factor for breast cancer: a prospective study,” Cancer Epidemiology Biomarkers and Prevention, vol. 11, no. 11, pp. 1361–1368, 2002. View at Google Scholar · View at Scopus
  29. M. Verheus, P. H. M. Peeters, S. Rinaldi et al., “Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC),” International Journal of Cancer, vol. 119, no. 3, pp. 659–667, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. A. H. Eliassen, S. S. Tworoger, C. S. Mantzoros, M. N. Pollak, and S. E. Hankinson, “Circulating insulin and C-peptide levels and risk of breast cancer among predominately premenopausal women,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 1, pp. 161–164, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. P. F. Bruning, J. M. G. Bonfrer, P. A. H. Van Noord, A. A. M. Hart, M. De Jong-Bakker, and W. J. Nooijen, “Insulin resistance and breast-cancer risk,” International Journal of Cancer, vol. 52, no. 4, pp. 511–516, 1992. View at Publisher · View at Google Scholar · View at Scopus
  32. M. E. Del Giudice, I. G. Fantus, S. Ezzat, G. McKeown-Eyssen, D. Page, and P. J. Goodwin, “Insulin and related factors in premenopausal breast cancer risk,” Breast Cancer Research and Treatment, vol. 47, no. 2, pp. 111–120, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Malin, Q. Dai, H. Yu et al., “Evaluation of the synergistic effect of insulin resistance and insulin-like growth factors on the risk of breast carcinoma,” Cancer, vol. 100, no. 4, pp. 694–700, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Schairer, D. Hill, S. R. Sturgeon et al., “Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women,” International Journal of Cancer, vol. 108, no. 5, pp. 773–779, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Bontenbal, A. M. Sieuwerts, J. G. M. Klijn et al., “Effect of hormonal manipulation and doxorubicin administration on cell cycle kinetics of human breast cancer cells,” British Journal of Cancer, vol. 60, no. 5, pp. 688–692, 1989. View at Google Scholar · View at Scopus
  36. A. G. Renehan, J. Frystyk, and A. Flyvbjerg, “Obesity and cancer risk: the role of the insulin-IGF axis,” Trends in Endocrinology and Metabolism, vol. 17, no. 8, pp. 328–336, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Pandini, F. Frasca, R. Mineo, L. Sciacca, R. Vigneri, and A. Belfiore, “Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved,” Journal of Biological Chemistry, vol. 277, no. 42, pp. 39684–39695, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Perseghin, G. Calori, G. Lattuada et al., “Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up,” Acta Diabetologica, vol. 49, no. 6, pp. 421–428, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. L. M. Berstein, J. O. Kvatchevskaya, T. E. Poroshina et al., “Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer,” Journal of Cancer Research and Clinical Oncology, vol. 130, no. 11, pp. 687–693, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. L. A. Witters, “The blooming of the French lilac,” Journal of Clinical Investigation, vol. 108, no. 8, pp. 1105–1107, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. D. R. Hadden, “Goat's rue—French lilac—Italian fitch—Spanish sainfoin: gallega officinalis and metformin: the Edinburgh connection,” The Journal of the Royal College of Physicians of Edinburgh, vol. 35, no. 3, pp. 258–260, 2005. View at Google Scholar · View at Scopus
  42. C. J. Bailey and C. Day, “Metformin: its botanical background,” Practical Diabetes International, vol. 21, no. 3, pp. 115–117, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. C. J. Bailey and R. C. Turner, “Metformin,” The New England Journal of Medicine, vol. 334, no. 9, pp. 574–579, 1996. View at Google Scholar · View at Scopus
  44. C. M. Rotella, M. Monami, and E. Mannucci, “Metformin beyond diabetes: new life for an old drug,” Current Diabetes Reviews, vol. 2, no. 3, pp. 307–315, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. V. M. Dilman, L. M. Berstein, and M. N. Ostroumova, “Metabolic immunodepression and metabolic immunotherapy. An attempt at improvement in immunologic response in breast cancer patients by correction of metabolic disturbances,” Oncology, vol. 39, no. 1, pp. 13–19, 1982. View at Google Scholar · View at Scopus
  46. V. M. Dilman, L. M. Berstein, T. P. Yevtushenko et al., “Preliminary evidence on metabolic rehabilitation of cancer patients,” Archiv fur Geschwulstforschung, vol. 58, no. 3, pp. 175–183, 1988. View at Google Scholar · View at Scopus
  47. L. M. Berstein, “Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond,” Future Oncology, vol. 6, no. 8, pp. 1313–1323, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. B. B. Kahn, T. Alquier, D. Carling, and D. G. Hardie, “AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism,” Cell Metabolism, vol. 1, no. 1, pp. 15–25, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. G. Zhou, R. Myers, Y. Li et al., “Role of AMP-activated protein kinase in mechanism of metformin action,” Journal of Clinical Investigation, vol. 108, no. 8, pp. 1167–1174, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. R. J. O. Dowling, M. Zakikhani, I. G. Fantus, M. Pollak, and N. Sonenberg, “Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells,” Cancer Research, vol. 67, no. 22, pp. 10804–10812, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Zakikhani, R. Dowling, I. G. Fantus, N. Sonenberg, and M. Pollak, “Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells,” Cancer Research, vol. 66, no. 21, pp. 10269–10273, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. W. H. Gotlieb, J. Saumet, M.-C. Beauchamp et al., “In vitro metformin anti-neoplastic activity in epithelial ovarian cancer,” Gynecologic Oncology, vol. 110, no. 2, pp. 246–250, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. I. N. Alimova, B. Liu, Z. Fan et al., “Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro,” Cell Cycle, vol. 8, no. 6, pp. 909–915, 2009. View at Google Scholar · View at Scopus
  54. K. Cusi, A. Consoli, and R. A. Defronzo, “Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 11, pp. 4059–4067, 1996. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Belfiore and F. Frasca, “IGF and insulin receptor signaling in breast cancer,” Journal of Mammary Gland Biology and Neoplasia, vol. 13, no. 4, pp. 381–406, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. A. M. Mulligan, F. P. O'Malley, M. Ennis, I. G. Fantus, and P. J. Goodwin, “Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer,” Breast Cancer Research and Treatment, vol. 106, no. 1, pp. 39–47, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Kalender, A. Selvaraj, S. Y. Kim et al., “Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner,” Cell Metabolism, vol. 11, no. 5, pp. 390–401, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Foretz, S. Hébrard, J. Leclerc et al., “Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state,” Journal of Clinical Investigation, vol. 120, no. 7, pp. 2355–2369, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. S. E. Inzucchi, R. M. Bergenstal, J. B. Buse et al., “Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD),” Diabetologia, vol. 55, no. 6, pp. 1577–1596, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Monami, C. Lamanna, D. Balzi, N. Marchionni, and E. Mannucci, “Sulphonylureas and cancer: a case-control study,” Acta Diabetologica, vol. 46, no. 4, pp. 279–284, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. S. L. Bowker, S. R. Majumdar, P. Veugelers, and J. A. Johnson, “Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin,” Diabetes Care, vol. 29, no. 2, pp. 254–258, 2006. View at Google Scholar · View at Scopus
  62. T. Patel, G. Hruby, K. Badani, C. Abate-Shen, and J. M. McKiernan, “Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin,” Urology, vol. 76, no. 5, pp. 1240–1244, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. H. A. Hirsch, D. Iliopoulos, P. N. Tsichlis, and K. Struhl, “Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission,” Cancer Research, vol. 69, no. 22, article 8832, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. A. DeCensi, M. Puntoni, P. Goodwin et al., “Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis,” Cancer Prevention Research, vol. 3, no. 11, pp. 1451–1461, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. Z. J. Zhang, Z. J. Zheng, R. Shi et al., “Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis,” Journal of Clinical Endocrinology and Metabolism, vol. 97, pp. 2347–2353, 2012. View at Google Scholar
  66. E. Giovannucci, “Metabolic syndrome, hyperinsulinemia, and colon cancer: a review,” The American Journal of Clinical Nutrition, vol. 86, no. 3, pp. 836S–842S, 2007. View at Google Scholar · View at Scopus
  67. C. Algire, L. Amrein, M. Zakikhani, L. Panasci, and M. Pollak, “Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase,” Endocrine-Related Cancer, vol. 17, no. 2, pp. 351–360, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Raimondi, P. Maisonneuve, and A. B. Lowenfels, “Epidemiology of pancreatic cancer: an overview,” Nature Reviews Gastroenterology and Hepatology, vol. 6, no. 12, pp. 699–708, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. M. B. Schneider, H. Matsuzaki, J. Haorah et al., “Prevention of pancreatic cancer induction in hamsters by metformin,” Gastroenterology, vol. 120, no. 5, pp. 1263–1270, 2001. View at Google Scholar · View at Scopus
  70. F. Xue and K. B. Michels, “Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence,” The American Journal of Clinical Nutrition, vol. 86, no. 3, pp. S823–S835, 2007. View at Google Scholar · View at Scopus
  71. R. J. Stevens, R. Ali, C. R. Bankhead et al., “Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials,” Diabetologia, vol. 55, pp. 2593–2603, 2012. View at Google Scholar
  72. R. C. Turner, C. A. Cull, V. Frighi, and R. R. Holman, “Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49),” Journal of the American Medical Association, vol. 281, no. 21, pp. 2005–2012, 1999. View at Publisher · View at Google Scholar · View at Scopus
  73. U. Smith and E. A. M. Gale, “Editorial: does diabetes therapy influence the risk of cancer?” Diabetologia, vol. 52, no. 9, pp. 1699–1708, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. S. K. Garg, I. B. Hirsch, and J. S. Skyler, “Editorial: insulin glargine and cancer-an unsubstantiated allegation,” Diabetes Technology and Therapeutics, vol. 11, no. 8, pp. 473–476, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. B. B. Duncan and M. I. Schmidt, “Metformin, cancer, alphabet soup, and the role of epidemiology in etiologic research,” Diabetes Care, vol. 32, no. 9, pp. 1748–1750, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. S. J. Pocock and L. Smeeth, “Insulin glargine and malignancy: an unwarranted alarm,” The Lancet, vol. 374, no. 9689, pp. 511–513, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. A. D. Hanchate, K. M. Clough-Gorr, A. S. Ash, S. S. Thwin, and R. A. Silliman, “Longitudinal patterns in survival, comorbidity, healthcare utilization and quality of care among older women following breast cancer diagnosis,” Journal of General Internal Medicine, vol. 25, no. 10, pp. 1045–1050, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Jiralerspong, S. L. Palla, S. H. Giordano et al., “Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer,” Journal of Clinical Oncology, vol. 27, no. 20, pp. 3297–3302, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. B.-X. Tan, W.-X. Yao, J. Ge et al., “Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes,” Cancer, vol. 117, no. 22, pp. 5103–5111, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. J. H. Lee, T. I. Kim, S. M. Jeon, S. P. Hong, J. H. Cheon, and W. H. Kim, “The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus,” International Journal of Cancer, vol. 7, no. 6, pp. 752–759, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. J. M. M. Evans, L. A. Donnelly, A. M. Emslie-Smith, D. R. Alessi, and A. D. Morris, “Metformin and reduced risk of cancer in diabetic patients,” British Medical Journal, vol. 330, no. 7503, pp. 1304–1305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. J. A. Johnson and S. L. Bowker, “Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials,” Diabetologia, vol. 54, no. 1, pp. 25–31, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. D. Soranna, L. Scotti, A. Zambon et al., “Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis,” Oncologist, vol. 17, pp. 813–822, 2012. View at Google Scholar
  84. C. J. Currie, C. D. Poole, and E. A. M. Gale, “The influence of glucose-lowering therapies on cancer risk in type 2 diabetes,” Diabetologia, vol. 52, no. 9, pp. 1766–1777, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. R. Ruiter, L. E. Visser, M. P. P. Van Herk-Sukel et al., “Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study,” Diabetes Care, vol. 35, no. 1, pp. 119–124, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. P. D. Home, S. E. Kahn, N. P. Jones, D. Noronha, H. Beck-Nielsen, and G. Viberti, “Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials,” Diabetologia, vol. 53, no. 9, pp. 1838–1845, 2010. View at Publisher · View at Google Scholar · View at Scopus